BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT07024862
- Locations
- 🇺🇸
Cardinal Health, Dublin, Ohio, United States
A Study to Assess Deucravacitinib Safety in Pregnancy
- Conditions
- Psoriasis (PsO)
- Interventions
- Drug: Other systemic treatments for PsO
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 900
- Registration Number
- NCT07017699
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Conditions
- Alzheimer Disease
- Interventions
- Drug: PlaceboDrug: Xanomeline/Trospium Chloride CapsuleDrug: Xanomeline Enteric Capsule
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 352
- Registration Number
- NCT07011732
- Locations
- 🇺🇸
Local Institution - 0098, Scottsdale, Arizona, United States
🇺🇸Local Institution - 1619, Scottsdale, Arizona, United States
🇺🇸Local Institution - 1657, Anaheim, California, United States
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Xanomeline/Trospium Chloride CapsuleDrug: PlaceboDrug: Xanomeline Enteric Capsule
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 352
- Registration Number
- NCT07011745
- Locations
- 🇺🇸
Local Institution - 0080, Chandler, Arizona, United States
🇺🇸Local Institution - 2609, Chandler, Arizona, United States
🇺🇸Local Institution - 2631, Chandler, Arizona, United States
Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan
- Conditions
- Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT07008820
- Locations
- 🇯🇵
Local Institution - 0001, Minato-ku, Tokyo, Japan
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- Conditions
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Interventions
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT07004972
- Locations
- 🇮🇳
Local Institution - 0014, Hyderabad, Andhra Pradesh, India
🇮🇳Local Institution - 0021, New Delhi, Delhi, India
🇮🇳Local Institution - 0005, New delhi, Delhi, India
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- Conditions
- Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer
- Interventions
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 234
- Registration Number
- NCT06997029
- Locations
- 🇺🇸
Local Institution - 0001, Birmingham, Alabama, United States
🇺🇸Local Institution - 0003, Fullerton, California, United States
🇺🇸Local Institution - 0013, Greenbrae, California, United States
Expanded Access for Mezigdomide
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT06994117
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 366
- Registration Number
- NCT06979453
- Locations
- 🇺🇸
Local Institution - 0025, Fountain Valley, California, United States
🇺🇸Local Institution - 0090, Fremont, California, United States
🇺🇸Local Institution - 0214, Northridge, California, United States
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 586
- Registration Number
- NCT06976216
- Locations
- 🇺🇸
Local Institution - 0173, Long Beach, California, United States
🇺🇸Local Institution - 0008, Redlands, California, United States
🇺🇸Local Institution - 0025, Basalt, Colorado, United States